Compare ELOG & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | ENSC |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.6M |
| IPO Year | 2024 | 2017 |
| Metric | ELOG | ENSC |
|---|---|---|
| Price | $1.00 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.4K | ★ 464.1K |
| Earning Date | 11-19-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,066,650.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $0.23 |
| 52 Week High | $2.93 | $2.75 |
| Indicator | ELOG | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 81.58 | 73.13 |
| Support Level | $0.82 | $0.47 |
| Resistance Level | $1.15 | $0.61 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 79.48 | 91.64 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.